Top 10 HIV/AIDS-Related Clinical Developments of 2011 (December 1, 2011)
David Alain Wohl, M.D., on HIV treatment as prevention; the dawning of pre-exposure prophylaxis (PrEP), but with women absent; the concept of "viremia copy-years"; the impact of race and gender on HIV treatment outcomes; setbacks for two treatment approaches involving Isentress; new hepatitis C therapies; a new once-daily HIV pill; the rising rates of HIV among black MSM; and what comes after "test and treat."
African Americans, Women Have Lower Virologic Response Rates in Both Arms of Head-to-Head Antiretroviral Trial (July 20, 2009)
Race and gender may prove to be a more critical factor than we think in virologic response to HIV medications. In the large HEAT study, which compared two first-line HAART regimens, Kimberly Smith, M.D., M.P.H., et al found that in both study arms, fewer African Americans (versus white patients) and females (versus males) achieved a viral load of less than 50 copies/mL.
In The 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO.com
The Body is a service of Remedy Health Media, LLC, 750 3rd Avenue, 6th Floor, New York, NY 10017. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.